Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease.
Crohn’s disease
microbiome
mucosal microbiota
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
received:
06
01
2020
pubmed:
26
5
2020
medline:
16
11
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Microbiota is most likely essential in the pathogenesis of Crohn's disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ileum, and the ileal microbiome is of particular interest. We have assessed the mucosa-associated microbiome in the inflamed and noninflamed ileum in patients with CD. Mucosa-associated microbiome was assessed by 16S rRNA sequencing of biopsies sampled 5 and 15 cm orally of the ileocecal valve or ileocolic anastomosis. Fifty-one CD patients and forty healthy controls (HCs) were included in the study. Twenty CD patients had terminal ileitis, with endoscopic inflammation at 5 cm, normal mucosa at 15 cm, and no history of upper CD involvement. Crohn's disease patients (n = 51) had lower alpha diversity and separated clearly from HC on beta diversity plots. Twenty-three bacterial taxa were differentially represented in CD patients vs HC; among these, Tyzzerella 4 was profoundly overrepresented in CD. The microbiome in the inflamed and proximal noninflamed ileal mucosa did not differ according to alpha diversity or beta diversity. Additionally, no bacterial taxa were differentially represented. The microbiome is similar in the inflamed and proximal noninflamed ileal mucosa within the same patients. Our results support the concept of CD-specific microbiota alterations and demonstrate that neither ileal sublocation nor endoscopic inflammation influence the mucosa-associated microbiome.
Sections du résumé
BACKGROUND
Microbiota is most likely essential in the pathogenesis of Crohn's disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ileum, and the ileal microbiome is of particular interest. We have assessed the mucosa-associated microbiome in the inflamed and noninflamed ileum in patients with CD.
METHODS
Mucosa-associated microbiome was assessed by 16S rRNA sequencing of biopsies sampled 5 and 15 cm orally of the ileocecal valve or ileocolic anastomosis.
RESULTS
Fifty-one CD patients and forty healthy controls (HCs) were included in the study. Twenty CD patients had terminal ileitis, with endoscopic inflammation at 5 cm, normal mucosa at 15 cm, and no history of upper CD involvement. Crohn's disease patients (n = 51) had lower alpha diversity and separated clearly from HC on beta diversity plots. Twenty-three bacterial taxa were differentially represented in CD patients vs HC; among these, Tyzzerella 4 was profoundly overrepresented in CD. The microbiome in the inflamed and proximal noninflamed ileal mucosa did not differ according to alpha diversity or beta diversity. Additionally, no bacterial taxa were differentially represented.
CONCLUSIONS
The microbiome is similar in the inflamed and proximal noninflamed ileal mucosa within the same patients. Our results support the concept of CD-specific microbiota alterations and demonstrate that neither ileal sublocation nor endoscopic inflammation influence the mucosa-associated microbiome.
Identifiants
pubmed: 32448900
pii: 5843656
doi: 10.1093/ibd/izaa107
pmc: PMC7737161
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-24Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Am J Gastroenterol. 2017 Dec;112(12):1840-1848
pubmed: 29087396
Indian J Microbiol. 2017 Sep;57(3):307-315
pubmed: 28904415
Surgeon. 2015 Dec;13(6):330-47
pubmed: 26049657
Cochrane Database Syst Rev. 2017 Jul 21;7:CD012351
pubmed: 28731502
J Clin Invest. 2014 Aug;124(8):3617-33
pubmed: 25003194
Aliment Pharmacol Ther. 2019 Oct;50(7):769-779
pubmed: 31396984
Inflamm Bowel Dis. 2015 Jun;21(6):1219-28
pubmed: 25844959
Gut Pathog. 2018 Nov 29;10:49
pubmed: 30519287
Inflamm Bowel Dis. 2019 Jan 10;25(2):217-225
pubmed: 30346536
Gut. 2016 Jun;65(6):954-62
pubmed: 26628508
Nat Med. 2019 Feb;25(2):323-336
pubmed: 30664783
Genome Biol. 2012 Apr 16;13(9):R79
pubmed: 23013615
Gastroenterology. 1990 Oct;99(4):956-63
pubmed: 2394349
Gut. 2017 Jan;66(1):50-58
pubmed: 26475633
Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Gut. 1984 Jun;25(6):665-72
pubmed: 6735250
Am J Clin Nutr. 2019 Sep 1;110(3):701-712
pubmed: 31291462
J Crohns Colitis. 2016 Mar;10(3):296-305
pubmed: 26574491
Inflamm Bowel Dis. 2016 Apr;22(4):817-25
pubmed: 26937623
Gastroenterology. 2002 Feb;122(2):512-30
pubmed: 11832465
Circ Res. 2016 Sep 30;119(8):956-64
pubmed: 27507222
J Crohns Colitis. 2016 Apr;10(4):462-71
pubmed: 26660940
J Crohns Colitis. 2017 Feb;11(2):191-203
pubmed: 27466174
BMC Gastroenterol. 2016 Feb 29;16:28
pubmed: 26922889
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Lancet. 1991 Sep 28;338(8770):771-4
pubmed: 1681159
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
PLoS One. 2013 Sep 24;8(9):e66934
pubmed: 24086242
Gut. 2020 Mar;69(3):462-472
pubmed: 31142586
Aliment Pharmacol Ther. 2018 Jan;47(1):26-42
pubmed: 29034981
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
Gastroenterology. 1998 Feb;114(2):262-7
pubmed: 9453485
Cell Host Microbe. 2014 Mar 12;15(3):382-392
pubmed: 24629344
Dis Mon. 2018 Feb;64(2):20-57
pubmed: 28826742
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627